Cell-Based Antibody Sensitivity Determination Method
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining antibody sensitivity and screening positive clone cell strains often use recombinant or denatured proteins, which do not accurately reflect binding capacity with proteins having natural conformation, leading to inaccurate results and resource wastage.
Innovation Solution
A method involving a solid-phase carrier, cells, and an antibody, where the antibody is adsorbed, incubated with cells, and then dyed and counted to determine sensitivity, allowing for accurate visualization of binding with natural antigens on cell surfaces, reducing labor and material costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If recombinant or denatured proteins are used for determining antibody sensitivity, then the determination process is simplified, but the accuracy of binding capacity assessment deteriorates
Solution Approach 1:
The patent changes the state of the antigen from denatured/recombinant to native conformational form. By using intact cells expressing native antigens on their surfaces instead of processed proteins, the method preserves the three-dimensional structure and conformational epitopes that antibodies recognize in physiological conditions, thereby improving measurement accuracy while maintaining procedural simplicity through standardized cell culture protocols
2Measurement precision
If conventional screening methods are used for positive clone cell strains, then labor and material costs increase, but screening accuracy may be compromised
Solution Approach 1:
The patent employs a self-service mechanism where the antibody-secreting hybridoma cells themselves serve as the source of both the antibody to be tested and the antigen-expressing cells for binding assessment. By culturing hybridoma cells and using their secreted antibodies to bind with target cells expressing native antigens, the system eliminates the need for external recombinant protein production and complex purification processes, significantly reducing material costs while maintaining high screening accuracy
Solution Approach 2:
The patent introduces a cell-based intermediary system where living cells expressing native antigens on their surfaces serve as the mediator between the antibody and the detection system. This cell intermediary preserves the natural conformational structure of antigens and enables direct binding assessment without requiring protein extraction, purification, or denaturation steps, thereby reducing both costs and improving accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides accurate determination of antibody sensitivity and clone cell strain quality by directly assessing binding with natural conformation antigens, improving screening efficiency and reducing resource wastage.
Implementation Method 1
adsorbing the antibody on the solid-phase carrier
Data Source
AI summary
A method and kit for determining antibody sensitivity and quality of a clone cell stain. The method comprises: obtaining a solid-phase carrier, cells and an antibody; adsorbing the antibody on the solid-phase carrier; incubating the cells and the antibody; preserving cells bound with the antibody; and dyeing and counting the cells bound with the antibody, so as to determine the antibody sensitivity or the quality of the clone cell stain based on the cell count. The kit comprises components used in the method.